K-PAX Pharmaceuticals is engaged in the development of products that support optimal mitochondrial metabolism.

KPAX002, our patented compound, is an enhanced, CNS stimulant, bolstered by our proprietary mitochondrial technology, now possessing the ability to treat fatigue in patients with neurodegenerative diseases. We have completed several clinical trials demonstrating that KPAX002 has excellent safety and efficacy in several disease states. 

Fatigue in neurodegenerative disorders represents a serious unmet medical need.  We are concurrently pursuing several indications: 

1) Parkinson's disease non-motor symptoms

2) Alzheimer's disease cognitive symptoms

3) Myalgic encephalomyelitis/CFS